JaLCDOI 10.18926/AMO/56079
FullText URL 72_3_315.pdf
Author Miyata, Yasuhiko| Saito M. , Akiko| Yano, Takahiro| Yoshida, Isao| Suehiro, Youko| Harada, Naoki| Nagai, Hirokazu|
Abstract In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowered due to the risks of comorbidities and organ function deterioration, and treatment outcomes are worse compared to younger patients. Very-elderly patients are often excluded from DLBCL clinical trials, and optimal treatments and dosages are not established. In this clinical trial, we examined the efficacy and safety of 6 courses of R-mini CHP therapy (cf., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]) in which vincristine is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life, as remission induction therapy in DLBCL patients aged≥80 years.
Keywords rituximab diffuse large B-cell lymphoma open-label single arm trial
Amo Type Clinical Study Protocol
Published Date 2018-06
Publication Title Acta Medica Okayama
Volume volume72
Issue issue3
Publisher Okayama University Medical School
Start Page 315
End Page 318
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29926011
JaLCDOI 10.18926/AMO/55863
FullText URL 72_2_197_n.pdf
Author Takase, Ken| Kada, Akiko| Iwasaki, Hiromi| Yoshida, Isao| Sawamura, Morio| Yoshio, Nobuyuki| Yoshida, Shinichiro| Iida, Hiroatsu| Otsuka, Maki| Takafuta, Toshiro| Ogata, Yuko| Suehiro, Youko| Hirabayashi, Yukio| Hishita, Terutoshi| Yoshida, Chikamasa| Ito, Takuo| Hidaka, Michihiro| Tsutsumi, Ikuyo| Saito, Akiko M.| Nagai, Hirokazu|
Abstract Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of <20, 000 /μL, or with <50, 000/ μL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.
Keywords idiopathic thrombocytopenic purpura short-term high-dose dexamethasone therapy open-label single-arm trial
Amo Type Clinical Study Protocol
Published Date 2018-04
Publication Title Acta Medica Okayama
Volume volume72
Issue issue2
Publisher Okayama University Medical School
Start Page 197
End Page 201
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29674771